Barclays PLC reissued their overweight rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report released on Wednesday morning. They currently have a $90.00 price target on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the stock. Jefferies Group LLC reiterated a hold rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 11th. BMO Capital Markets reiterated an outperform rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Robert W. Baird reiterated an outperform rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Thursday, July 13th. J P Morgan Chase & Co restated an overweight rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Finally, BidaskClub upgraded shares of Gilead Sciences from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. Twelve research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. Gilead Sciences presently has a consensus rating of Buy and an average price target of $85.86.
Shares of Gilead Sciences (NASDAQ GILD) traded down 1.40% on Wednesday, hitting $81.41. The stock had a trading volume of 4,682,689 shares. The firm has a market capitalization of $106.32 billion, a P/E ratio of 8.84 and a beta of 1.14. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a 50 day moving average of $81.81 and a 200-day moving average of $72.01.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the business posted $3.08 EPS. Equities analysts predict that Gilead Sciences will post $8.75 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Gilead Sciences’ (GILD) Overweight Rating Reaffirmed at Barclays PLC” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.com-unik.info/2017/10/12/gilead-sciences-gild-overweight-rating-reaffirmed-at-barclays-plc.html.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last ninety days. 1.30% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in GILD. Waldron LP grew its stake in Gilead Sciences by 20.4% in the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 1,752 shares in the last quarter. Nikko Asset Management Americas Inc. grew its stake in Gilead Sciences by 67.2% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 9,700 shares of the biopharmaceutical company’s stock worth $659,000 after buying an additional 3,900 shares in the last quarter. Parsec Financial Management Inc. grew its stake in Gilead Sciences by 63.0% in the 1st quarter. Parsec Financial Management Inc. now owns 79,205 shares of the biopharmaceutical company’s stock worth $5,380,000 after buying an additional 30,614 shares in the last quarter. Oakwood Capital Management LLC CA grew its stake in Gilead Sciences by 1.3% in the 1st quarter. Oakwood Capital Management LLC CA now owns 52,100 shares of the biopharmaceutical company’s stock worth $3,539,000 after buying an additional 655 shares in the last quarter. Finally, Meyer Handelman Co. grew its stake in Gilead Sciences by 2.7% in the 1st quarter. Meyer Handelman Co. now owns 380,900 shares of the biopharmaceutical company’s stock worth $25,871,000 after buying an additional 9,900 shares in the last quarter. 73.98% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.